A study of human tumor cells implanted in mice from the MacPherson Lab at Fred Hutch describes a new way to screen for the ...

But Harding’s doctors offered only tests and prescriptions that led nowhere. One prescribed an inhaler and, when it didn’t ...

Makers of organoids and cell models cheered the decision and said it will bolster the development of precision medicines, ...

Updated Phase 2 data to be presented at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, in combination with atezolizumab in patients with metastatic microsatellite stable colorectal ...

Xilio anticipates nominating a development candidate for its PSMA program in the ATACR format in the third quarter of 2025 and submitting an IND application in the first quarter of 2027. PSMA has ...

Prostate cancer, UTIs, and hormonal drug uptake lead growth; Asia Pacific emerges as fastest-growing region as awareness and access to care improve.Austin, May 08, 2025 (GLOBE NEWSWIRE) -- ...

Many men with metastatic hormone-sensitive prostate cancer have not received recommended first-line therapies due to clinicians’ unfamiliarity with treatment guidelines and misinformation about ...

As a novel calcineurin inhibitor with proven efficacy in improving renal outcomes, LUPKYNIS addresses a high unmet medical need. With increas ...

As a novel calcineurin inhibitor with proven efficacy in improving renal outcomes, LUPKYNIS addresses a high unmet medical need. With increasing awareness, supportive guidelines, and potential ...